Keywords: avandia, does, raise, cv, risk, relative, antidiabetics

Avandia does not raise CV risk relative to other antidiabetics, but questions remain

Article | 09 June 2009

Print This

A large study of Avandia (rosiglitazone), sponsored by UK drug major GlaxoSmithKline in a bid to dispel safety concerns surrounding ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in